MedTrace Logo

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

NCT04066725 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2022-02-18

No results posted yet for this study

Summary

This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.

Conditions

  • Melanoma (Skin)

Interventions

DRUG

Aspirin 81 mg

Participants will be given ASA 81 mg orally once daily for a total of 60 days

DRUG

Aspirin 325mg

Participants will be given ASA 325 mg orally once daily for a total of 60 days

DRUG

Placebo oral tablet

Participants will be given placebo orally once daily for a total of 60 days

Sponsors & Collaborators

Principal Investigators

  • Douglas Grossman, MD · Huntsman Cancer Institute/ University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-25
Primary Completion
2021-03-19
Completion
2021-03-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04066725 on ClinicalTrials.gov